Clinical Trial Update: Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Visugromab with nivolumab, with or without docetaxel, for second-line metastatic non-squamous non-small cell lung cancer; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Visugromab (Visugromab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: CatalYm GmbH | Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Status: RECRUITING